Do hypoechoic endometrial cystic appearances before embryo transfer affect pregnancy rates in frozen-thawed cycles?

The endometrium, the inner lining of the uterus, is the site where an embryo implants and develops during pregnancy. It provides both structural anchorage and nourishment essential for early embryonic growth [ 1 ]. Successful live birth following in vitro fertilization (IVF) depends on two critical factors: the transfer of morphologically and genetically competent embryos, and a receptive endometrium capable of supporting implantation and continued development. Although several methods allow detailed evaluation of embryo quality, techniques for assessing endometrial receptivity remain limited [ 2 ]. Transvaginal sonography is the most widely used approach to evaluate endometrial thickness (ET) and endometrial pattern (EP) [ 2 , 3 ]. Numerous studies have demonstrated significant associations between ET and reproductive outcomes, including miscarriage and live birth rates (LBR). A threshold of approximately 7 mm has been frequently reported, below which pregnancy rates decline and miscarriage rates increase. In addition to thickness, the presence of a trilaminar EP is considered a critical indicator of receptivity, and is at least as important as the measured thickness itself [ 4 – 6 ]. Alterations in the echogenicity of the central line within this trilaminar pattern have been associated with reduced clinical pregnancy rates (CPR) [ 7 ]. Structural abnormalities such as intrauterine adhesions, polyps, and fibroids can distort the endometrial cavity, producing a dysmorphic uterine appearance that disrupts the EP and adversely affects pregnancy outcomes [ 8 ]. Furthermore, the occurrence of hypoechoic cystic lesions (HCL) during endometrial preparation has raised concern regarding impaired endometrial function and possible cycle cancellation. Even when embryo transfer proceeds, these lesions may indicate a reduced likelihood of pregnancy. The present study therefore aimed to evaluate the effect of HCL on pregnancy outcomes in patients undergoing frozen–thawed embryo transfer (FET).

This study evaluated the impact of cystic hypoechoic lesions on IVF outcomes and found that their presence did not adversely affect clinical pregnancy or LBR in patients with adequate ET (>7 mm) and a trilaminar pattern. However, given the limited sample size, larger prospective studies are warranted to confirm these findings and further elucidate the clinical relevance of such lesions in endometrial assessment before embryo transfer.

The main limitation of this study is its retrospective design, which may involve selection bias and incomplete data capture. The relatively small sample size (44 patients per group) provided adequate power only to detect large differences in live-birth rates; smaller effects cannot be excluded. Although all scans were performed by experienced clinicians, some misclassification between HCL and other intra-endometrial findings (e.g., fluid, polyps, focal hyperplasia) is possible. The lack of centralized or blinded image review may have introduced observer variability, and unmeasured factors such as mild adenomyosis could have influenced outcomes. Serum progesterone on the transfer day was not measured, limiting assessment of luteal adequacy. Larger prospective studies with standardized imaging and hormonal monitoring are needed to confirm these results.

This retrospective cohort study included FET cycles performed between January 2022 and January 2024 at the IVF Department of Acıbadem Maslak Hospital. Ethical approval was obtained from the Acıbadem Mehmet Ali Aydınlar University Medical Research Ethics Committee prior to data collection ( Approval No: 2025-06/257 ). As anonymized data from existing medical records were used, the requirement for individual informed consent was waived in accordance with institutional and national regulations. Patients were classified into two groups according to endometrial appearance on transvaginal ultrasonography: those with HCL (HCL group) and those with a normal trilaminar EP (control group). Only the first FET cycle per patient was analyzed to eliminate potential bias from repeated treatments. All included cases had an ET of ≥7 mm. Exclusion criteria included maternal age > 40 years, a history of recurrent implantation failure or recurrent pregnancy loss, uterine anomalies such as intrauterine adhesions or dysmorphic uterus, and male partners with azoospermia. Patients with previous uterine surgery (myomectomy, septum resection, or adhesiolysis) or sonographic evidence of intrauterine adhesions, endometrial polyps, or fibroids were excluded to prevent confounding effects on endometrial morphology and implantation outcomes. All patients received a gonadotropin-releasing hormone (GnRH) agonist (Lucrin Depot 3.75 mg/0.1 mL, leuprolide acetate) on day 21 of the menstrual cycle preceding endometrial preparation. On cycle days 2–3, transvaginal sonography was performed to evaluate the endometrial cavity and adnexa, and serum estradiol and progesterone levels were measured. Oral estrogen (Estrofem 2 mg) was given twice daily for the first five days, three times daily for the next five days, and four times daily thereafter. On day 15 of estrogen administration, patients were reevaluated. No HCL was observed at baseline (cycle days 2–3); these lesions were first identified during sonographic evaluation on day 15, coinciding with the measurement of ET. Cycles were cancelled if ET was < 7 mm. For patients with adequate endometrial development (≥7 mm), serum progesterone and estradiol levels were reassessed. Those with progesterone levels 200 pg/mL initiated progesterone supplementation to optimize endometrial–embryo synchronization and prevent premature luteinization, consistent with the findings of Yuceturk et al . (2025), who demonstrated that serum hormone levels at specific time points are predictive of FET outcomes [ 9 ]. Luteinizing hormone levels were not measured, as all patients were under complete GnRH-agonist suppression. Blood samples were collected between 08:00 and 10:00 on both the day of endometrial assessment and the day of embryo transfer. Luteal support consisted of subcutaneous prolutex (25 mg twice daily) combined with vaginal progesterone capsules (Progestan 200 mg three times daily). Embryo transfer timing was based on the duration of progesterone exposure: cleavage-stage embryos were transferred after three full days (P + 3) and blastocysts after five full days (P + 5). To ensure uniform luteal support, patients with serum progesterone levels <14.97 ng/mL on the day of transfer were excluded. Only FET cycles without preimplantation genetic testing (PGT) were included to eliminate bias related to embryo chromosomal status, and all transfers were performed as single-embryo transfer (SET) to maintain consistency between groups. Pregnancy outcomes were defined according to standard clinical criteria. A biochemical pregnancy was defined as a positive serum β-hCG (>10 mIU/mL) without sonographic evidence of a gestational sac. A clinical pregnancy was defined as the visualization of an intrauterine gestational sac with fetal cardiac activity at approximately 5–6 weeks of gestation. Miscarriage referred to any pregnancy loss occurring before 25 weeks of gestation, including biochemical losses. Live birth was defined as the delivery of a liveborn infant at or beyond 25 weeks of gestation. No ectopic pregnancies were identified, and biochemical and clinical pregnancies were both included in the denominators for clinical pregnancy and live-birth rate calculations. The primary outcome was the LBR, while secondary outcomes included the CPR, miscarriage rate, and biochemical pregnancy rate. The size of HCLs was further analyzed as an exploratory variable to assess potential correlations with reproductive outcomes. Statistical analyses were performed using IBM SPSS Statistics version 30.0 (IBM Corp., Armonk, NY, USA). Data normality was assessed with the Shapiro–Wilk test. Normally distributed continuous variables were expressed as mean ± standard deviation (SD), and non-normally distributed variables as median [interquartile range, IQR]. Categorical variables were presented as number ( n ) and percentage (%). Between-group comparisons for continuous variables were conducted using the independent-samples t-test for normally distributed data and the Mann–Whitney U test for non-normally distributed data. Categorical variables were compared using the Pearson chi-square or Fisher’s exact test when more than 20% of expected cell counts were <5. Effect sizes for binary outcomes were reported as odds ratios (OR) with 95% confidence intervals (CI). For multi-category variables, such as embryo-transfer pattern and cause of infertility, only overall χ² p-values were reported to minimize multiplicity and unstable estimates. Associations between continuous variables, such as hypoechoic lesion size and reproductive outcomes, were evaluated using the Mann–Whitney U test. A two-tailed p value <0.05 was considered statistically significant. A total of 88 patients were included in the analysis, comprising 44 patients with HCLs (HCL group) and 44 controls with a normal trilaminar EP ( Fig 1 ). The mean age of all participants was 32.5 ± 6.2 years, with a mean body mass index (BMI) of 26.8 ± 6.7 kg/m 2 , mean ET of 11.1 ± 2.3 mm, and mean infertility duration of 5.7 ± 4.0 years ( Table 1 ). When compared by group, no significant differences were observed in age (32.8 ± 6.3 vs 32.2 ± 6.1 years, p  = 0.74), BMI (27.1 ± 6.5 vs 26.6 ± 6.9 kg/m 2 , p  = 0.81), ET (11.2 ± 2.4 vs 11.0 ± 2.3 mm, p  = 0.72), or duration of infertility (5.8 ± 3.9 vs 5.6 ± 4.2 years, p  = 0.84). Effect sizes were uniformly small, indicating well-matched baseline characteristics. In the HCL group, the median lesion diameter was 0.9 mm [IQR 0.3–1.8], suggesting that the observed lesions were typically small and localized. Values are presented as mean ± standard deviation (SD) or median [IQR] where appropriate. Cohen’s d represents standardized effect size (small = 0.2, medium = 0.5, large = 0.8). † Data reported for patients with detectable hypoechoic cystic lesions only (HCL group). The LBR was the primary outcome, while the CPR, biochemical pregnancy rate, and miscarriage rate were analyzed as secondary outcomes ( Table 2 ). The size of HCLs was examined as an exploratory variable. Clinical pregnancy was achieved in 30 patients (68.2%) in both groups ( p  = 1.00; OR = 1.00, 95% CI 0.41–2.46). Biochemical pregnancy occurred in 2 (4.5%) and 1 (2.3%) cases in the HCL and control groups, respectively ( p  = 1.00; OR = 2.05, 95% CI 0.18–23.44). Miscarriage occurred in 5 (20.5%) and 7 (15.9%) patients ( p  = 1.00; OR = 0.68, 95% CI 0.20–2.33), while LBRs were 23 (52.3%) and 22 (50.0%) in the HCL and control groups, respectively ( p  = 0.67; OR = 1.10, 95% CI 0.47–2.53). None of these differences were statistically significant, indicating that the presence of HCLs did not adversely influence pregnancy or live-birth outcomes following FET. Further analysis showed no significant association between HCL size and reproductive outcomes. The median diameter was 1.80 mm [IQR 1.20–2.00] in patients who conceived and 1.65 mm [IQR 1.30–3.00] in those who did not ( p  = 0.612). Similarly, lesion size did not differ between patients with and without live birth ( p  = 0.795) ( Table 2 ). * Number of patients with evaluable data. The distribution of embryo-transfer patterns was identical between groups (χ² p  = 1.000) ( Table 3 ). In both cohorts, 5 (11.4%) patients received one embryo on day 3, 14 (31.8%) received one embryo on day 5, 6 (13.6%) received two embryos on day 3, and 19 (43.2%) received two embryos on day 5. Per-category odds ratios were 1.00 with wide confidence intervals (e.g., one embryo on day 5: OR = 1.00, 95% CI 0.44–2.28), confirming comparable embryo-transfer distributions between groups. Infertility etiologies were comparable between groups (χ² p  = 0.444) ( Table 3 ). In the HCL group, male-factor, diminished ovarian reserve, advanced maternal age, and unexplained infertility were present in 43.2%, 6.8%, 13.6%, and 36.4% of patients, respectively, with no tubal-factor cases. Corresponding rates in the control group were 38.6%, 11.4%, 2.3%, and 38.6%, with 9.1% having tubal-factor infertility. None of the differences were statistically significant (all p  > 0.05), indicating that HCLs were not associated with the underlying infertility profile. Overall, the presence or size of HCLs did not influence implantation, clinical pregnancy, or live-birth outcomes following FET, suggesting that small, localized endometrial lesions are clinically insignificant in terms of reproductive prognosis.

(CSV)